Major funding for the Technology Platforms has been provided by the Government of Canada through Canadian Foundation for Innovation and Western Economic Diversification; the US National Institutes of Health through the National Cancer Institute; and the generous support of the BC Cancer Foundation and its donors.
The technology and clinical platforms at Canada's Michael Smith Genome Sciences Centre are staffed by teams of professional scientists with expertise in several areas of genomics research. These teams support researchers and collaborators in BC and around the world in work addressing topical questions in the life sciences.
The bioinformatics group at the GSC participates in a diverse number of areas on computational genomic analysis such as expression profiling, gene regulation, comparative genomics analysis, genome assembly, and laboratory information management. The platform has nearly 90 computational biologists, software programmers, and informatics specialists working with all GSC activity areas to provide data analysis and management solutions. The development of data analysis tools for high-throughput sequencing is a major focus of the bioinformatics group, with key projects and publications already in place.
High-throughput large-scale DNA analysis facility designed to maximize capacity while maintaining efficiency, scalability and flexibility. The platform is one of the largest platform of its type in Canada and is well recognized internationally.
The GSC operates Illumina HiSeq X instruments, Illumina HiSeq 2500 v4 instruments, miSeq instruments and NextSeq instruments. All HISeq 2500 instruments have been converted to the latest platform, with each instrument capable of generating one terabase of sequence data per run. Library construction for Illumina sequencing is available for whole genome (including PCR-free and FFPE), transcriptome (ssRNA-seq), exome and custom capture, microRNA,and chromatin immunoprecipitation (ChIP). The GSC has to date constructed over 50,000 Illumina libraries, contributing to many projects and publications.
The Proteomics group at the GSC performs protein and post-translational modification identification on protein samples using high pressure liquid chromatography coupled to nano-electrospray mass spectrometry. Current applications include protein-protein interaction mapping, and protein phosphorylation site detection and quantitation.
The drug discovery platform performs high-throughput virtual screening using leading molecular docking software and high performance computing resources to find novel therapeutics for human diseases.
Providing sustainable and scalable clinical diagnostic genomic testing for the population of British Columbia.
A translational research facility, CTAG provides clinical grade services to the academic and private sector clients.